ImageneBio, Inc. (IMA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $43.22M
Last updated: Nov 17, 2026 at 11:03 AM ET
ImageneBio, Inc. (IMA) Stock Forecast
Analysts expect ImageneBio (IMA) to earn -$3.43 per share in the fiscal year ending Dec 31, 2026. Of 4 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 2 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 4 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 75% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 75.0% |
| Hold | 0 | 0.0% |
| Sell | 1 | 25.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 4
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a larger loss.
- Fiscal year ending Dec 31, 2026
- -$3.43
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$4.18
- EPS consensus
- Next report
- Mar 1, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$3.43 | -$3.48 to -$3.37 | 2 |
| Dec 31, 2027 | -$4.18 | -$5.48 to -$2.91 | 3 |
Quarterly Estimates
The EPS consensus falls from -$0.97 for the quarter ending Dec 31, 2026 to -$1.14 for the quarter ending Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.97 | -$1.00 to -$0.96 | 5 |
| Mar 31, 2027 | -$1.14 | -$1.14 to -$1.14 | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 2 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$3.18.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$3.43 | -$3.31 | -$3.31 | -$3.31 | -$3.18 | N/A |
| Fiscal year ending Dec 31, 2027 | -$4.18 | -$4.31 | -$4.31 | -$4.31 | -$3.73 | N/A |
| Quarter ending Mar 31, 2027 | -$1.14 | -$1.07 | -$1.07 | -$1.07 | -$0.99 | N/A |
Frequently Asked Questions About IMA
What is the IMA stock forecast?
Consensus analyst estimates put ImageneBio's EPS at -$3.43 for the fiscal year ending Dec 31, 2026. The consensus rating from 4 analysts is Hold.
How do analysts rate IMA stock?
Of 4 analysts covering ImageneBio, 0 rate it Strong Buy, 3 Buy, 0 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from IMA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$3.43, with estimates from -$3.48 to -$3.37 from 2 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$4.18, with estimates from -$5.48 to -$2.91 from 3 analysts.
How many analysts cover IMA?
4 analysts rate ImageneBio stock, and 2 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
IMA pages: Overview, Earnings, Forecast, Financials, Competitors